COG2 and coronary artery disorder: According to the 2018 ACC/AHA [27], the 2019 ESC/EAS [28], and the Adult Treatment Panel III (ATP III) cholesterol guidelines [29], LDL-C was considered the major cause of CAD and treated as the primary target for therapy, while other lipids were used as the secondary or supplementary therapeutic targets.